Bieżący numer
Archiwum
Online first
O czasopiśmie
Redakcja
Rada Naukowa
Wydawca
Standardy etyczne i procedury
Bazy indeksacyjne
Recenzenci
Recenzenci Honorowi
Prenumerata
Kontakt
Najczęściej czytane artykuły
Dla autorów
Opłata za przetwarzanie artykułu (APC)
Książki i Konferencje
Książki
Konferencje
SARS CoV-2/COVID-19
PRACA ORYGINALNA
Vitamin D supply in patients with rheumatic diseases in Poland. A pilot study
1
Department of Rheumatology, Rehabilitation and Internal Medicine, Poznan University of Medical Sciences, Poland
2
Department of Clinical Auxology and Pediatric Nursing, Poznan University of Medical Sciences, Poland
Data nadesłania: 29-01-2021
Data ostatniej rewizji: 24-04-2021
Data akceptacji: 27-04-2021
Data publikacji online: 11-07-2021
Data publikacji: 16-07-2021
Reumatologia 2021;59(3):146-152
SŁOWA KLUCZOWE
DZIEDZINY
SLE, zespół Sjögrena i zespół antyfosfolipidowy - etiologia, patogeneza, obraz kliniczny i leczenieTwardzina układowa, myositis i powiązane zespoły - etiologia, patogeneza, obraz kliniczny i leczenieZapalenia naczyń - etiologia, patogeneza, obraz kliniczny i leczenieOsteoporoza
STRESZCZENIE
Introduction:
In rheumatic diseases, vitamin D supply is recommended as part of the prophylaxis and treatment of osteoporosis, especially in patients undergoing glucocorticoid therapy, but also due to its immunoregulatory and anti-inflammatory properties. We aimed to evaluate serum 25-hydroxyvitamin D [25(OH)D3] levels in Polish patients with systemic sclerosis (SSc), systemic lupus erythematosus (SLE) and granulomatosis with polyangiitis (GPA), in relation to various clinical parameters, and to assess the initial range of doses for the purpose of further research.
Material and methods:
112 patients (39 with SLE, 44 with SSc and 29 with GPA), referred to the Department of Rheumatology and Internal Medicine in Poznan, Poland, were enrolled in this retrospective study. Demographic and clinical data were collected, including 25(OH)D3 serum levels, vitamin D supplementation doses and season of blood sampling.
Results:
Mean (SD) serum 25(OH)D3 concentrations were 31 (19.4) ng/ml for SLE, 28.8 (12.5) ng/ml for SSc and 28 (15.2) ng/ml for GPA, and they did not significantly differ between the groups. Vitamin D levels below the optimal range were found in 43.8% of SLE, 65.9% of SSc and 72.4% of GPA patients. 80% of patients reported vitamin D intake, with a mean daily dose of 1398 IU for SLE, 1345 IU for SSc and 1689 IU for GPA. Vitamin D insufficiency and deficiency were frequent among patients with rheumatic diseases, independently of the diagnosis and season.
Conclusions:
Patients with rheumatic diseases seem to require higher doses of vitamin D than recommended for the general population. The present results indicate the necessity to use higher initial doses of vitamin D in this group of patients (2000 to 4000 UI) and to maintain the dose of vitamin D regardless of the change of seasons.
In rheumatic diseases, vitamin D supply is recommended as part of the prophylaxis and treatment of osteoporosis, especially in patients undergoing glucocorticoid therapy, but also due to its immunoregulatory and anti-inflammatory properties. We aimed to evaluate serum 25-hydroxyvitamin D [25(OH)D3] levels in Polish patients with systemic sclerosis (SSc), systemic lupus erythematosus (SLE) and granulomatosis with polyangiitis (GPA), in relation to various clinical parameters, and to assess the initial range of doses for the purpose of further research.
Material and methods:
112 patients (39 with SLE, 44 with SSc and 29 with GPA), referred to the Department of Rheumatology and Internal Medicine in Poznan, Poland, were enrolled in this retrospective study. Demographic and clinical data were collected, including 25(OH)D3 serum levels, vitamin D supplementation doses and season of blood sampling.
Results:
Mean (SD) serum 25(OH)D3 concentrations were 31 (19.4) ng/ml for SLE, 28.8 (12.5) ng/ml for SSc and 28 (15.2) ng/ml for GPA, and they did not significantly differ between the groups. Vitamin D levels below the optimal range were found in 43.8% of SLE, 65.9% of SSc and 72.4% of GPA patients. 80% of patients reported vitamin D intake, with a mean daily dose of 1398 IU for SLE, 1345 IU for SSc and 1689 IU for GPA. Vitamin D insufficiency and deficiency were frequent among patients with rheumatic diseases, independently of the diagnosis and season.
Conclusions:
Patients with rheumatic diseases seem to require higher doses of vitamin D than recommended for the general population. The present results indicate the necessity to use higher initial doses of vitamin D in this group of patients (2000 to 4000 UI) and to maintain the dose of vitamin D regardless of the change of seasons.
REFERENCJE (38)
1.
Murdaca G, Tonacci A, Negrini S, et al. Autoimmunity reviews emerging role of vitamin D in autoimmune diseases: an update on evidence and therapeutic implications. Autoimmun Rev 2019; 18: 102350, DOI: 10.1016/j.autrev.2019.102350.
2.
Stumpf WE, Sar M, Reid FA, et al. Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science 1979; 206: 1188–1190, DOI: 10.1126/science.505004.
3.
Grygiel-Górniak B, Puszczewicz M. Vitamin D – a new look in medicine and rheumatology. Postepy Hig Med Dosw (Online) 2014; 68: 359–368, DOI: 10.5604/17322693.1097426 [Article in Polish].
4.
Myszka M, Klinger M. The immunomodulatory role of vitamin D. Postepy Hig Med Dosw (Online) 2014; 68: 865–878, DOI: 10.5604/17322693.1110168 [Article in Polish].
5.
Saponaro F, Marcocci C, Zucchi R. Vitamin D status and cardiovascular outcome. J Endocrinol Invest 2019; 42: 1285–1290, DOI: 10.1007/s40618-019-01057-y.
6.
Pittas AG, Lau J, Hu FB, Dawson-Hughes B. Review: the role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 2007; 92: 2017–2029, DOI: 10.1210/jc.2007-0298.
7.
Lappe JM, Travers-Gustafson D, Davies KM, et al. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2008; 87: 794–794, DOI: 10.1093/ajcn/87.3.794 [Erratum].
8.
Yamshchikov AV, Desai NS, Blumberg HM, et al. Vitamin D for treatment and prevention of infectious diseases: a systematic review of randomized controlled trials. Endocr Pract 2009; 15: 438–449, DOI: 10.4158/EP09101.ORR.
9.
Adorini L, Penna G. Control of autoimmune diseases by the vitamin D endocrine system. Nat Clin Pract Rheumatol 2008; 4: 404–412, DOI: 10.1038/ncprheum0855.
10.
Theodoratou E, Tzoulaki I, Zgaga L, Ioannidis J. Vitamin D and multiple health outcomes : umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. BMJ 2014; 2035: 1–19, DOI: 10.1136/bmj.g2035.
11.
Abrahamsen B, Harvey NC. The role of vitamin D supplementation in patients with rheumatic diseases. Nat Rev Rheumatol 2013; 9: 411–422, DOI: 10.1038/nrrheum.2013.71.
12.
Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol 2017; 69: 1521–1537, DOI: 10.1002/art.40137.
13.
Duru N, van der Goes MC, Jacobs JW, et al. EULAR evidence- based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2013; 72: 1905–1913, DOI: 10.1136/annrheumdis-2013-203249.
14.
Wang XR, Xiao JP, Zhang JJ, Wu YG. Decreased serum/plasma vitamin D levels in SLE patients: a meta-analysis. Curr Pharm Des 2018; 24: 4466–4473, DOI: 10.2174/1381612825666190111145848.
15.
Adami G, Rossini M, Bogliolo L, et al. An exploratory study on the role of vitamin D supplementation in improving pain and disease activity in rheumatoid arthritis. Mod Rheumatol 2019; 29: 1059–1062, DOI: 10.1080/14397595.2018.1532622.
16.
Lin J, Liu J, Davies ML, Chen W. Serum vitamin D level and rheumatoid arthritis disease activity: review and meta-analysis. PLoS One 2016; 11: e0146351, DOI: 10.1371/journal.pone. 0146351.
17.
Amital H, Szekanecz Z, Szücs G, et al. Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D? Ann Rheum Dis 2010; 69: 1155–1157, DOI: 10.1136/ard.2009.120329.
18.
Kerr GS, Sabahi I, Richards JS, et al. Prevalence of vitamin D insufficiency/deficiency in rheumatoid arthritis and associations with disease severity and activity. J Rheumatol 2011; 38: 53–59, DOI: 10.3899/jrheum.100516.
19.
Rossini M, Bongi SM, La Montagna G, et al. Vitamin D deficiency in rheumatoid arthritis: prevalence, determinants and associations with disease activity and disability. Arthritis Res Ther 2010; 12: R216, DOI: 10.1186/ar3195.
20.
Guan SY, Cai HY, Wang P, et al. Association between circulating 25-hydroxyvitamin D and systemic lupus erythematosus: a systematic review and meta-analysis. Int J Rheum Dis 2019; 22: 1803–1813, DOI: 10.1111/1756-185X.13676.
21.
An L, Sun MH, Chen F, Li JR. Vitamin D levels in systemic sclerosis patients: a meta-analysis. Drug Des Devel Ther 2017; 11: 3119–3125, DOI: 10.2147/DDDT.S144860.
22.
Giuggioli D, Colaci M, Cassone G, et al. Serum 25-OH vitamin D levels in systemic sclerosis: analysis of 140 patients and review of the literature. Clin Rheumatol 2017; 36: 583–590, DOI: 10.1007/s10067-016-3535-z.
23.
Arnson Y, Amital H, Agmon-Levin N, et al. Serum 25-OH vitamin D concentrations are linked with various clinical aspects in patients with systemic sclerosis: a retrospective cohort study and review of the literature. Autoimmun Rev 2011; 10: 490–494, DOI: 10.1016/j.autrev.2011.02.002.
24.
Trombetta AC, Smith V, Gotelli E, et al. Vitamin D deficiency and clinical correlations in systemic sclerosis patients: a retrospective analysis for possible future developments. PLoS One 2017; 12: e0179062, DOI: 10.1371/journal.pone.0179062.
25.
Caimmi C, Bertoldo E, Pozza A, et al. Vitamin D serum levels and the risk of digital ulcers in systemic sclerosis: a longitudinal study. Int J Rheum Dis 2019; 22: 1041–1045, DOI: 10.1111/1756-185X.13554.
26.
Perez MO, Oliveira RM, Levy-Neto M, et al. Serum 25-hydroxyvitamin D levels in patients with granulomatosis with polyangiitis: association with respiratory infection. Clinics (Sao Paulo) 2017; 72: 723–728, DOI: 10.6061/clinics/2017(12)02.
27.
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725–1725, DOI: 10.1002/art.1780400928.
28.
van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2013; 72: 1747–1755, DOI: 10.1136/annrheumdis-2013-204424.
29.
Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum 2010; 33: 1101–1107, DOI: 10.1002/art.1780330807.
30.
Rusińska A, Płudowski P, Walczak M, et al. Vitamin D supplementation guidelines for general population and groups at risk of vitamin D deficiency in Poland – recommendations of the Polish Society of Pediatric Endocrinology and Diabetes and the Expert Panel With Participation of National Specialist C. Front Endocrinol (Lausanne) 2018; 9: 246, DOI: 10.3389/fendo. 2018.00246.
31.
Płudowski P, Ducki C, Konstantynowicz J, Jaworski M. Vitamin D status in Poland. Pol Arch Med Wewn 2016; 126: 530–539, DOI: 10.20452/pamw.3479.
32.
Kmieć P, Żmijewski M, Lizakowska-Kmieć M, Sworczak K. Widespread vitamin D deficiency among adults from northern Poland (54°N) after months of low and high natural UVB radiation. Endokrynol Pol 2015; 66: 30–38, DOI: 10.5603/EP. 2015.0006.
33.
Vacca A, Cormier C, Piras M, et al. Vitamin D deficiency and insufficiency in 2 independent cohorts of patients with systemic sclerosis. J Rheumatol 2009; 36: 1924–1929, DOI: 10.3899/jrheum. 081287.
34.
Groseanu L, Bojinca V, Gudu T, et al. Low vitamin D status in systemic sclerosis and the impact on disease phenotype. Eur J Rheumatol 2016; 3: 50–55, DOI: 10.5152/eurjrheum.2015.0065.
35.
Aggarwal A, Yadav AK, Ramachandran R, et al. Bioavailable vitamin D levels are reduced and correlate with bone mineral density and markers of mineral metabolism in adults with nephrotic syndrome. Nephrology 2016; 21: 483–489, DOI: 10.1111/nep.12638.
36.
Banerjee S, Basu S, Akhtar S, et al. Free vitamin D levels in steroid-sensitive nephrotic syndrome and healthy controls. Pediatr Nephrol 2020; 35: 447–454, DOI: 10.1007/s00467-019-04433-1.
37.
Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992; 327: 1637–1642, DOI: 10.1056/NEJM199212033272305.
38.
Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337: 670–676, DOI: 10.1056/NEJM199709043371003.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Udostępnij
ARTYKUŁ POWIĄZANY
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
Przetwarzamy dane osobowe zbierane podczas odwiedzania serwisu. Realizacja funkcji pozyskiwania informacji o użytkownikach i ich zachowaniu odbywa się poprzez dobrowolnie wprowadzone w formularzach informacje oraz zapisywanie w urządzeniach końcowych plików cookies (tzw. ciasteczka). Dane, w tym pliki cookies, wykorzystywane są w celu realizacji usług, zapewnienia wygodnego korzystania ze strony oraz w celu monitorowania ruchu zgodnie z Polityką prywatności. Dane są także zbierane i przetwarzane przez narzędzie Google Analytics (więcej).
Możesz zmienić ustawienia cookies w swojej przeglądarce. Ograniczenie stosowania plików cookies w konfiguracji przeglądarki może wpłynąć na niektóre funkcjonalności dostępne na stronie.
Możesz zmienić ustawienia cookies w swojej przeglądarce. Ograniczenie stosowania plików cookies w konfiguracji przeglądarki może wpłynąć na niektóre funkcjonalności dostępne na stronie.
